Treace Medical Clocks 40% Jump In Q4 Sales On Higher Volume, FY22 Guidance Better Than Expected

  • Treace Medical Concepts Inc TMCI Q4 FY21 sales increased 39% to $33.4 million, beating the consensus of $32.27 million, driven by an increased number of Lapiplasty procedure kits sold and an expanded customer base.
  • A gross margin of 81.1% increased 220 basis points from the same period last year, on volume increases without a corresponding rise in certain fixed costs and a higher blended average selling price.
  • Fourth-quarter revenue contribution from bunion-focused direct sales channel was 58% of sales, an increase from an average of 39% in Q4 of FY20.
  • New interim data from the ALIGN3D study demonstrated continued positive radiographic and patient-reported outcomes at 12- and 24- months following the Lapiplasty procedure. 
  • A low recurrence rate was also maintained, with 0.9% and 0.0% observed at 12- and 24- months post-surgery, respectively.
  • The Company reported a Q4 EPS loss of $(0.12), a shift from the income of $0.05 a year ago.
  • Treace Medical held cash & cash equivalents of $105.8 million at the end of 2021.
  • Guidance: Treace expects FY22 sales of $125 million - $130 million, +32% - 38% Y/Y, versus the consensus of $124.25 million.
  • Price Action: TMCI shares closed 1.31% lower at $20.41 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!